CADEX GENOMICS
LIVE

Serial Number

88296676

Owner

Cadex Genomics, Corp.

Attorney

James K. Stronski

First Use Date

Apr 16, 2019

Filing Date

Feb 11, 2019

Add to watchlist:

No watchlists yet
View on USPTO

CADEX GENOMICS Trademark

Serial Number: 88296676 • Registration: 6159028

CADEX GENOMICS is a trademark filed by Cadex Genomics, Corp. on February 11, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Cadex Genomics, Corp. (2 trademarks)

541 Jefferson Avenue, Suite 100
Redwood City, CA 94063

Entity Type: 03

Trademark Details

Filing Date

February 11, 2019

Registration Date

September 22, 2020

First Use Anywhere

April 16, 2019

First Use in Commerce

April 16, 2019

Published for Opposition

December 10, 2019

Goods & Services

Medical diagnostic assays for testing of bodily fluids, namely, assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Medical diagnostic test media in the form of reagents used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; medical diagnostic kits comprised of medical diagnostic reagents and assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy

Medical testing for diagnostic or treatment purposes, namely, for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy

Medical and scientific research in the field of medical diagnostic assays and clinical testing services for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Research and development in the pharmaceutical and biotechnology fields, namely, research and development in the development of testing and information services related to medical diagnostic assays and clinical tests, and medical diagnostic kits used to conduct medical diagnostic assays and clinical tests

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 22, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Sep 22, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 18, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 15, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 14, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 13, 2020 AITU
USE AMENDMENT FILED
Aug 4, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 4, 2020 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 4, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 10, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 10, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 20, 2019 NONP
ASSIGNED TO LIE
Nov 1, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 28, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 26, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 25, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 29, 2019 GNRN
NON-FINAL ACTION E-MAILED
Apr 29, 2019 GNRT
NON-FINAL ACTION WRITTEN
Apr 29, 2019 CNRT
ASSIGNED TO EXAMINER
Apr 23, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 5, 2019 NWOS
NEW APPLICATION ENTERED
Feb 14, 2019 NWAP